# Efficacy and Biomarker Development for Lung Cancer Treated With Immune Checkpoint Inhibitors

> **NCT05055908** · PHASE3 · RECRUITING · sponsor: **Hunan Province Tumor Hospital** · enrollment: 12000 (estimated)

## Conditions studied

- Lung Cancer

## Interventions

- **DRUG:** Pemetrexed plus Pembrolizumab
- **DRUG:** Pembrolizumab
- **DRUG:** Pemetrexed

## Key facts

- **NCT ID:** NCT05055908
- **Lead sponsor:** Hunan Province Tumor Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-10-01
- **Primary completion:** 2025-07-01
- **Final completion:** 2027-09-14
- **Target enrollment:** 12000 (ESTIMATED)
- **Last updated:** 2024-08-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05055908

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05055908, "Efficacy and Biomarker Development for Lung Cancer Treated With Immune Checkpoint Inhibitors". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT05055908. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*